Mecasermin rinfabate
Combination of | |
---|---|
IGFBP-3 | Binding protein |
Clinical data | |
Trade names | Iplex |
AHFS/Drugs.com | Monograph |
Routes of administration | Injection |
ATC code | |
Identifiers | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Mecasermin rinfabate (
It is similar in action to mecasermin, but with fewer side effects (such as hypoglycemia).[3]
Potential uses
Mecasermin rinfabate was developed by INSMED corporation for the treatment of
On March 11, 2009 the
Myotonic muscular dystrophy
Iplex was investigated in a Phase II clinical study at the University of Rochester School of Medicine, with funding provided by the Muscular Dystrophy Association and the National Institutes of Health. This Phase II program studied the safety and tolerability of once-daily, subcutaneous injection of Iplex in patients with MMD. While patients with MMD showed significant increases in total muscle weight, testosterone levels, and LDL levels, and significant decreases in triglyceride and HDL levels, functional assays such as grip strength and walk tests did not show improvement.
HIV-associated adipose redistribution syndrome
Iplex is also being explored as a possible therapy for HIV- Associated Adipose Redistribution Syndrome (HARS). Data is being collected from a Phase II open-label clinical study directed by Morris Schambelan, M.D., a professor of medicine at University of California San Francisco. Dr Schambelan serves as Chief of Endocrinology and Director of the General Clinical Research Center at San Francisco General Hospital. This study is designed to evaluate the safety and efficacy of Iplex treatment with the primary goal of determining the effects of Iplex on
Retinopathy of prematurity
Clinical work is at an earlier stage in the development of Iplex to treat Retinopathy of Prematurity (ROP). This disease, affecting an estimated 14,000 to 16,000
Amyotrophic lateral sclerosis
In January 2007, INSMED announced that the Italian Ministry of Health requested INSMED corporation to make Iplex available to treat Italian patients sufferings from ALS.
IGF-1, the main component of Iplex, was the subject of a recent clinical trial in ALS. It involved 330 people with ALS from 20 ALS treatment centres across the United States. The drug was injected under the skin (subcutaneous delivery) in a randomized double-blinded placebo-controlled trial – this is the gold standard way of conducting a clinical trial. At the end of the two-year treatment period, there were no differences between people with ALS who received IGF-1 and those who received placebo in muscle strength, the need for a tracheostomy for breathing, or survival, indicating that IGF-1 provided patients no benefit. The current results are published in the November 25 issue of Neurology.[6] The researchers were led by Eric J. Sorenson, MD, from the Mayo Clinic in Rochester, Minnesota "While this is very disappointing, at least it was definitive and gives, I think, a pretty definitive answer, at least for this strategy for this drug," Dr. Sorenson said. However, he added, "there is still a great deal of evidence that the IGF-1 pathway can be beneficial to people who have ALS, but just not the way we administered it."[7]
Novel methods of delivering IGF-1 in a more selected fashion are now under way, including the use of viral mediators or stem cells. Two previous phase 3 trials of IGF-1 in ALS showed inconsistent results: 1 trial, carried out in North America, did find a benefit, whereas the other, a European trial, did not confirm the earlier findings. "The results of our study most resemble those of the previous European study, with no benefit in either survival or functional scales,", De Sorenson concludes. "It is disappointing that we were unable to confirm the benefit that was noted in the previous North American study."
Conclusive evidence points, what Iplex (and any form of IGF-1) can't slow progression in human ALS. Lot of sites that have published articles about the link between Lyme disease and ALS are sponsored by clinics specializing in the treatment of chronic Lyme disease, or by the sellers of products for treating this, or both.[8]
Myotonia congenita
Myotonia congenita is a genetic muscle disorder. The two main types of myotonia congenita are
References
- S2CID 71237825.
- PMID 17380212.
- S2CID 29352034.
- ^ Jennifer Corbett Dooren (2009-03-10). "FDA Allows Use of Drug for ALS". Wall Street Journal. Retrieved 2009-03-11.
- ^ Amy Harmon (2009-05-17). "Fighting for a Last Chance at Life". The New York Times. Retrieved 2009-05-17.
- PMID 19029516.
- ^ Jeffrey, Susan (2008-11-26). "No Benefit of Treatment With IGF-1 in ALS". Medscape. Retrieved 2008-12-06.
- PMID 19701824.)
{{cite journal}}
: CS1 maint: others (link